The city of Ann Arbor, Michigan, currently has 180 active clinical trials seeking participants for Cancer research studies.
Optimization of MRI for Radiation Therapy
Recruiting
Currently, appropriate patients undergo MRI imaging with immobilization and sequences optimized for diagnostic radiology purposes. Using a mutual information algorithm, these images are then registered to a treatment planning CT obtained with custom immobilization to minimize intra-and inter-treatment motion and positional variation. This image registration process is time-consuming and introduces additional layers of geometric uncertainty into what should be a highly precise treatment planning... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: Univeristy of Michigan, Ann Arbor, Michigan
Conditions: Cancer Liver, Cancer Brain, Cancer Head &Neck, Cancer Pelvis
Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors
Recruiting
The study will determine the recommended Phase 2 dose (RP2D) of livmoniplimab (ABBV-151) administered as monotherapy and in combination with budigalimab (ABBV-181) as well as to assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of livmoniplimab alone and in combination with budigalimab. The study will consist of 2 parts: dose escalation and dose expansion.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/29/2024
Locations: Univ Michigan Med Ctr /ID# 221129, Ann Arbor, Michigan
Conditions: Advanced Solid Tumors Cancer
A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer
Recruiting
This trial will evaluate the efficacy and safety of various therapies in patients with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated non-small cell lung cancer (NSCLC) tumors that meet protocol-specified biomarker criteria
Gender:
All
Ages:
18 years and above
Trial Updated:
04/29/2024
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Non-small Cell Lung Cancer
The Vallania Study: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening
Recruiting
This protocol is a case-control, multicenter, diagnostic study to collect blood samples to support the development of blood-based screening tests for multiple cancers.
Gender:
All
Ages:
30 years and above
Trial Updated:
04/26/2024
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Cancer
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
Recruiting
The primary objective is to assess overall sensitivity and specificity of Oncoguard™ Liver for hepatocellular cancer (HCC) detection in a surveillance population.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/26/2024
Locations: VA Ann Arbor Healthcare System, Ann Arbor, Michigan +1 locations
Conditions: Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatitis B, Cirrhosis, Liver Cancer
Prosthesis Guided Speech Rehabilitation of T1/T2 Cancers of the Tongue
Recruiting
This study will fill a scientific gap in the current knowledge providing data for evaluation of the palatal augmentation prosthesis (PAP) as a therapeutic modality in a robust scientific randomized prospective clinical trial. Positive outcomes from this study have the potential to dramatically alter the most common issues of oral cancer therapy, namely speech and swallowing functions. Patients will have been diagnosed with a cancer lesion on their tongue requiring surgery and removal of part of... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/26/2024
Locations: University of Michigan Department of Oral and Maxillofacial Surgery and Hospital Dentistry, Ann Arbor, Michigan
Conditions: Tongue Neoplasms, Tongue Cancer, Oral Cancer
Ribociclib (LEE011) Rollover Study for Continued Access
Recruiting
This study is to allow continued use of ribociclib (LEE011) as single agent or in combination with other investigational treatments in patients benefitting from treatment in an eligible Novartis-sponsored ribociclib (LEE011) study that has reached its primary objective(s) or has been halted for other reasons.
Gender:
All
Ages:
80 years and below
Trial Updated:
04/25/2024
Locations: The Regents of the University of Michigan, Ann Arbor, Michigan
Conditions: Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies
ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Recruiting
This phase II trial investigates how well ZEN-3694, enzalutamide, and pembrolizumab work in treating patients with castration-resistant prostate cancer that has spread to other places in the body (metastatic). ZEN-3694 blocks the expression of the MYC gene to prevent cellular growth in certain types of tumors, including castrate resistant prostate cancer. Enzalutamide has been shown to block testosterone from reaching prostate cancer cells by binding to a receptor on prostate cancer cells, calle... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Metastatic Prostate Small Cell Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Gilteritinib for the Treatment of ALK NSCLC
Recruiting
This phase I trial is studying the safety, side effects, and best dose of gilteritinib in treating patients with stage IV ALK positive non-small cell lung cancer (NSCLC) who have progressed on other treatments. While there are many approved targeted drugs for ALK NSCLC, resistance to these drugs frequently occur. Giltertinib is a drug that is already FDA approved for the treatment of a specific type of leukemia. However, studies using ALK positive lung cancer cells demonstrate activity of gilter... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
Conditions: Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer
Recruiting
CLN-081-001 is a Phase 1/2, open label, multi-center study of CLN-081 in patients with non-small cell lung cancer (NSCLC) harboring EGFR (epidermal growth factor receptor) exon 20 insertion mutations, to characterize the safety, determine the recommended Phase 2 dose (RP2D), and evaluate efficacy.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: University of Michigan Health System - University Hospital, Ann Arbor, Michigan
Conditions: Non Small Cell Lung Cancer, EGFR Exon 20 Mutation
Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy
Recruiting
This study is designed to see if we can lower the chance of side effects from radiation in patients with breast, kidney, small cell lung cancer, non-small cell lung cancer or melanoma that has spread to the brain and who are also being treated with immunotherapy, specifically immune checkpoint inhibitor (ICI) therapy. This study will compare the usual care treatment of single fraction stereotactic radiosurgery (SSRS) given on one day versus fractionated stereotactic radiosurgery (FSRS), which is... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/18/2024
Locations: Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor, Michigan
Conditions: NSCLC, Renal Cell Carcinoma, Breast Carcinoma, Melanoma, Brain Metastases, Adult, Non-small Cell Lung Cancer, SCLC, Small-cell Lung Cancer
Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors
Recruiting
This phase III trial studies how well bupropion works in reducing cancer related fatigue in cancer survivors. Bupropion is a drug that is used to treat depression, as well as to help people quit smoking. Cancer and its treatment can cause fatigue. Giving bupropion may improve cancer related fatigue in cancer survivors.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/18/2024
Locations: Saint Joseph Mercy Hospital, Ann Arbor, Michigan
Conditions: Be Diagnosed With Cancer and Have Completed Systemic Therapy